Pharmaceuticals
Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab Has Priced
SHANGHAI and GAITHERSBURG, Md., Feb. 9, 2021 /PRNewswire/ -- A registered follow-on public offering by certain pre-IPO shareholders (the "Selling Shareholders") of 3,283,950 American depositary shares (the "ADSs" and such offering, the "ADS Offering") of I-Mab (the "Company") (Nasdaq: IMAB), a c...
2021-02-09 21:00
9489
Proposed Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab
SHANGHAI and GAITHERSBURG, Md., Feb. 5, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the commencement of a proposed registered underwritten pu...
2021-02-06 06:27
9366
I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S.
SHANGHAI and GAITHERSBURG, Md., Feb. 5, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics, today announced multiple clinical advancements for its proprieta...
2021-02-05 21:00
5772
I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China
SHANGHAI and GAITHERSBURG, Md., Feb. 4, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in a phase 2 clinic...
2021-02-04 21:00
5180
Covid-19 Drug Duo Achievements: GoldenBiotech's New Drug Antroquinonol (HOCENA) Trial Receives Positive Response from DMC Review and Licenses for 4 Countries
TAIPEI, Feb. 4, 2021 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132)("GoldenBiotech"), a leading Taiwanese biopharmaceutical company, announced that it has made two achievements for its Covid-19 new drug candidate Antroquinonol® (HOCENA®): receiving positive response after DMC review in Ph...
2021-02-04 18:41
2073
Eucure Biopharma Announces Encouraging Antitumor Activity of Its anti-CD40 Antibody in PD-1 Refractory Ocular Melanoma when Combined with Junshi Biosciences' Toripalimab
BOSTON and BEIJING, Feb. 3, 2021 /PRNewswire/ -- Eucure Biopharma, a biopharmaceutical company dedicated to developing immuno-oncology antibody drugs, announced that its investigational anti-CD40 antibody drug (YH003), when combined with Junshi Biosciences' anti-PD-1 antibody Toripalimab (TUOYI®)...
2021-02-03 23:45
5488
More Patients Set to Benefit as Kanghong Pharmaceutical Targets New Indications with Conbercept
CHENGDU, China, Feb. 3, 2021 /PRNewswire/ -- Chengdu Kanghong Pharmaceutical Group ("Kanghong", SHE: 002773), has received Special Protocol Assessments from the Food and Drug Administration for three new indications for its biologic drug conbercept. The drug is an anti-VEGF fusion protein, approv...
2021-02-03 22:00
4371
Longevity Acquisition Corporation Announces 4D pharma Update on Oncology Program
NEW YORK, Feb. 3, 2021 /PRNewswire/ -- Longevity Acquisition Corporation (NASDAQ: LOAC) (the "Company"), a publicly-traded special purpose acquisition company, announced today that onFebruary 3, 2021, 4D pharma plc (AIM: DDDD) ("4D pharma"), a pharmaceutical company leading the development of Liv...
2021-02-03 22:00
6685
Nippon Express (Thailand) Obtains GDP Certification for Domestic Transport Services
TOKYO, Feb. 2, 2021 /PRNewswire/ -- Nippon Express (Thailand) Co., Ltd. (hereinafter, "NE Thailand"), a local subsidiary of Nippon Express Co., Ltd. based inTokyo, has obtained Good Distribution Practice (GDP) certification effectiveTuesday, December 22, 2020, evidencing its compliance with stand...
2021-02-02 14:00
1417
Kintor's GT20029 IND for PROTAC AR Degrader Was Accepted by NMPA
SUZHOU, China, Feb. 2, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939) is pleased to announce that the investigational new drug ("IND") application of GT20029 for androgenetic alopecia and acne vulgaris indications has been accepted by the National Medical Products Administration (...
2021-02-02 12:11
3993
DW Healthcare Partners Invests in Parnell
PARK CITY, Utah, Feb. 2, 2021 /PRNewswire/ -- DW Healthcare Partners ("DWHP") a healthcare-focused private equity firm, announced the completion of its investment in Parnell Pharmaceuticals Holdings Ltd (OTC: PARNF) ("Parnell" or the "Company"). Founded over 50 years ago inAustralia, Parnell is a...
2021-02-02 08:23
3074
Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet
* Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial * Clover plans to initiate a global phase 2/3 trial in the first half of 2021 with an interim analysis for vaccine efficacy pot...
2021-02-01 14:00
3509
DWHP Announces Expiration And Final Results Of Its Cash Tender Offer For All Outstanding Ordinary Shares Of Parnell Pharmaceuticals Holdings Ltd.
PARK CITY, Utah, Jan. 30, 2021 /PRNewswire/ -- DW Healthcare Partners V, L.P. ("DWHP"), announced today the expiration and final results of its previously announced cash tender offer (the "Tender Offer") to purchase all of the outstanding ordinary shares (the "Tender Securities") of Parnell Phar...
2021-01-30 07:38
9310
Nippon Express Bangladesh Obtains GDP Certification for Air Cargo Import/Export Services
TOKYO, Jan. 29, 2021 /PRNewswire/ -- Nippon Express Bangladesh Ltd. (hereinafter, "NE Bangladesh"), a local subsidiary of Nippon Express Co., Ltd. based inTokyo, has obtained Good Distribution Practice (GDP) certification effectiveSunday, December 13, 2020, evidencing its compliance with standard...
2021-01-29 15:00
1582
Immunoforge's 'PF1801' Is Designated as Orphan Drug by FDA
SEOUL, South Korea, Jan. 28, 2021 /PRNewswire/ -- Immunoforge, the company specializing in the development of new drugs for rare musculoskeletal diseases (Representatives: An Seong-Min and Jang Gi-Ho), announced that their new drug candidate PF1801 has been designated as the FDA orphan drug for t...
2021-01-28 22:00
1958
Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA
INCHEON, South Korea, Jan. 26, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company's track record as a premiere CDO serv...
2021-01-27 08:26
6168
I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer
SHANGHAI, China and PLANEGG/MUNICH, Germany, Jan. 25, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), and MorphoSys (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) today announced that the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety, tolerabili...
2021-01-26 05:05
3467
BioNTech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine
MAINZ, Germany and SHANGHAI, China, 25 Jan. 2021 /PRNewswire/ -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") andShanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "Group"; Stock Code: 600196.SH, 02196.HK) today announced that according to the Food and Health Bureau of ...
2021-01-26 01:18
5875
China Biologic Announces Extraordinary General Meeting of Shareholders
BEIJING, Jan. 25, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that it has called an extraordinary general meeting of shareholders (the "EGM...
2021-01-25 21:44
9017
Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for Patients with Severe COVID-19
TAIPEI and SAN DIEGO, Jan. 21, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that the first patient has enrolled into an investi...
2021-01-22 12:00
1812
Week's Top Stories
Most Reposted
Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery
[Picked up by 323 media titles]
2025-01-13 09:05
URBAN REVIVO Celebrates Lunar New Year with Unique Collaboration with Artist Mercedes Bellido
[Picked up by 293 media titles]
2025-01-13 10:44
Gen Z Travelers Drive Buy Now, Plan Later Travel Bookings by Over 20%: Fliggy's 2024 Buy Now Plan Later Travel Insight
[Picked up by 286 media titles]
2025-01-10 16:04RuggON Launches VIKING II: Transforming Fleet Management with Unmatched Technology and Flexibility
[Picked up by 286 media titles]
2025-01-14 21:00
VANTAGE FOUNDATION SUPPORTS GRAB INDONESIA IN EMPOWERING WOMEN DRIVER-PARTNER
[Picked up by 280 media titles]
2025-01-09 18:26
Most Read
Hyundai Motor Group Partners with NVIDIA to Accelerate Development of AI Solutions for Future Mobility
2025-01-10 01:00
20322
AIMA Unveils Game-Changing 2025 eBike Lineup at CES: Better Performance, More Freedom
2025-01-09 02:34
6480
RingConn Takes Center Stage at CES 2025 with Innovative Wearables: Gen 2 and Gen 2 Air
2025-01-11 01:00
5610
Boqii Announces ADS Ratio Change
2025-01-11 05:30
4945
Sino Land Included in Dow Jones Sustainability World Index
2025-01-10 22:01
4926
